FIELD: immunology.
SUBSTANCE: disclosed is a method of producing a polypeptide which specifically binds to staphylococcus protein A and does not bind to human FcRn containing two polypeptides, wherein the first and second polypeptides contain mutations H310A, H433A and Y436A.
EFFECT: disclosed invention can find further application in producing polypeptides with reduced clearance and longer half-life.
8 cl, 45 tbl, 20 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| EMBODIMENTS OF Fc-REGION WITH MODIFIED BINDING PROPERTIES OF FcRn AND PROTEIN A | 2015 |
|
RU2713131C1 |
| NOVEL VERSIONS OF INTERLEUKIN-2 FOR TREATING CANCER | 2020 |
|
RU2833537C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY GLYCOENGINEERING | 2014 |
|
RU2831409C2 |
